Teva Confirms Denosumab Is Part Of Its Biosimilar Pipeline
Prolia Biosimilar Asset Is In Phase III Development
Teva has officially confirmed one of its many biosimilar assets is a rival to Amgen’s Prolia (denosumab) to treat osteoporosis in postmenopausal women. Sandoz, Celltrion and Samsung Bioepis are among those that have previously thrown their hats into the ring.
